Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Mesothelioma

• Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
• MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
• HTL0039732 in Participants With Advanced Solid Tumours
• Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
• MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
• Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
• Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
• Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
• First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
• PRO1184 for Advanced Solid Tumors
• A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
• A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers
• A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
• Oral AMXT 1501 Dicaprate in Combination With IV DFMO
• AMT-151 in Patients With Selected Advanced Solid Tumours
• Niraparib Efficacy in Patient With Unresectable Mesothelioma
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
• Immunological Variables Associated to ICI Toxicity in Cancer Patients
• OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
• Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
• --- SMARTEST Trial---
• Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
• A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
• Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
• Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
• A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
• Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
• A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
• A Study of NX-1607 in Adults With Advanced Malignancies
• A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
• A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
• Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
• Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
• Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
• UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
• Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
• A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
• A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
• Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
• Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
• Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
• Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
• Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
• A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
• Olaparib in Patients With HRD Malignant Mesothelioma
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
• Intravenous Magnesium in Patients Receiving Cisplatin
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
• Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma
• Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
• The IMmunotherapy Pleural 5-ALA PDT
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
• Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
• DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
• HMPL-453 in Advanced Malignant Mesothelioma
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
• Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
• Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Rhabdomyosarcoma in Pediatric Patients, T.O.A.S.T. I.T. Study
• Pembrolizumab + Defactinib In Pleural Mesothelioma
• DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
• Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
• Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
• A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
• Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
• A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
• Diadem to Investigate the Activity and Safety of Durvalumab
• A Study of CPI-0209 in Patients With Advanced Tumors
• Phase I Trial HIPEC With Nal-irinotecan
• A Study of SGN-CD228A in Advanced Solid Tumors
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
• MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
• INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
• Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
• APG-2449 in Patients With Advanced Solid Tumors
• Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
• Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
• Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
• A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
• BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
• Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
• Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
• Dose Individualization of Pemetrexed - IMPROVE-I
• Dose Individualization of Pemetrexed - IMPROVE-III
• Dose Individualization of Pemetrexed - IMPROVE-II
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
• DENdritic Cell Immunotherapy for Mesothelioma
• Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
• A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
• Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
• Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
• Olaparib in People With Malignant Mesothelioma
• First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
• Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
• Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
• Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
• Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
• Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
• CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
• Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
• Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
• PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
• Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
• Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
• Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
• A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
• Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
• Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
• Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
• Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas
• Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
• Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
• Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
• A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
• Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
• Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
• Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
• Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
• Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
• Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
• 18F-FSPG PET/CT for Cancer Patients on Therapy
• MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
• A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
• Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
• Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
• Nivolumab in Patients With Recurrent Malignant Mesothelioma
• Four Versus Six Cycles of Pemetrexed/Platinum for MPM
• Isolated Thoracic Perfusion (ITP-F) for MPM
• Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
• TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
• Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
• Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
• A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
• MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
• Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
• A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
• Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
• Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
• ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
• Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
• αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
• Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
• Vinorelbine in Mesothelioma
• Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy
• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
• Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
• Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
• Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C
• Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
• Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
• Nintedanib (BIBF 1120) in Mesothelioma
• Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
• Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
• Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
• Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
• A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
• The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
• A Study of LY3023414 in Participants With Advanced Cancer
• A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
• Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
• Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
• Mithramycin for Lung, Esophagus, and Other Chest Cancers
• Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
• Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
• A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
• SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
• Amatuximab for High Mesothelin Cancers
• SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
• Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
• A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
• A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
• Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
• Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
• Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
• Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
• Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
• Combination Gene Transfer and Chemotherapy
• Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
• AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
• NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
• Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
• Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
• A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
• Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
• Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
• Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
• Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
• Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
• Sorafenib in Previously Treated Malignant Mesothelioma
• An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
• An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
• Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
• Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
• Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
• An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
• A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
• Dasatinib in Resectable Malignant Pleural Mesothelioma
• Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
• N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
• Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
• Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
• Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
• An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
• Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
• A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
• Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
• Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
• Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
• Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
• Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
• Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
• Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
• Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
• Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
• Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
• Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
• PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
• Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma
• Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
• A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
• Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
• Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
• Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
• Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
• Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
• Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
• Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
• S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
• Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
• A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
• Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
• Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
• Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
• Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
• Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
• Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
• Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
• Alanosine in Treating Patients With Cancer
• Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
• Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
• PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
• ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
• Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
• Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
• Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
• Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
• Gefitinib in Treating Patients With Malignant Mesothelioma
• Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
• Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
• Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
• Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
• Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
• SU5416 in Treating Patients With Malignant Mesothelioma
• Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
• Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
• Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
• Capecitabine in Treating Patients With Malignant Mesothelioma
• Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
• Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
• S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
• Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
• Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
• ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
• Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
• Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
• High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma